This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Improved Outcome in Fluvoxamine-Treated Patients With SSRI-Induced Sexual Dysfunction

Michael D. Banov

Published: December 31, 1999

Article Abstract

Letter to the Editor

Sir: I read with interest the recent article by Nafziger and colleagues1 (March 1999 issue) describing the incidence of sexual dysfunction in 20 healthy volunteers who were administered fluvoxamine, 150 mg/day, for 2 to 4 weeks as part of a clinical pharmacology trial. The authors conclude that healthy normal adults (presumably free of underlying psychopathology) had a 35% rate of reporting symptoms of sexual impairment during fluvoxamine therapy as based on data from a structured adverse event questionnaire. The implication is that this result would also be true in patients who are taking fluvoxamine for obsessive-compulsive disorder or depression, and that the rate for fluvoxamine would then be comparable to the rate reported for other agents in the selective serotonin reuptake inhibitor (SSRI) class.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 60

Quick Links: